Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | FPR3 | P25089 | 2/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2937827 | 1.00 | CYP2D6 (0.42) | CYP2D6FDPSDRD2DRD3FPR3 | |
| SCHEMBL3335001 | 1.00 | CYP2D6 (0.42) | CYP2D6FDPSDRD2DRD3FPR3 | |
| Hydrochloric Acid SCHEMBL27126809 | 0.98 | DRD2 (0.41) | CYP2D6FDPSDRD2DRD3FPR3 | |
| Hydrochloric Acid SCHEMBL27007558 | 0.98 | DRD2 (0.41) | CYP2D6FDPSDRD2DRD3FPR3 | |
| SCHEMBL3088560 | 0.94 | FDPS (0.47) | CYP2D6FDPSMEN1KMT2AMITF | |
| SCHEMBL1598094 | 0.94 | FDPS (0.47) | CYP2D6FDPSMEN1KMT2AMITF | |
| SCHEMBL20186812 | 0.94 | FDPS (0.47) | CYP2D6FDPSMEN1KMT2AMITF | |
| Hydrochloric Acid SCHEMBL17114350 | 0.92 | FDPS (0.46) | CYP2D6FDPSMEN1KMT2AMITF | |
| SCHEMBL17513288 | 0.85 | — | — | |
| SCHEMBL23201076 | 0.85 | DRD2 (0.39) | CYP2D6FDPSDRD2DRD3FPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941903-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Saniona A/S (DK) | 2022-01-26 | — | — | EP | claimed |
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| US-12043640-B2 | Prodrugs of STAT3 inhibitors | TVARDI THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2024146643-A1 | COMPOUND CONTAINING 2-METHYL-2-(3-(PIPERIDIN-3-YL)PHENOXY)-2-METHYLPROPANAMIDE SKELETON | 江苏明生聚太生物科技有限公司 | 2024-07-11 | — | — | WO | disclosed |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217989-A1 | Heteroaryl Fluoroalkenes As DGK Inhibitors | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| WO-2024107434-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024108100-A1 | HETEROARYL FLUOROALKENES AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240018172-A1 | PRODRUGS OF STAT3 INHIBITORS | TVARDI OPERATING COMPANY, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023137406-A1 | HETEROARYL COMPOUNDS AS HPK1 INHIBITORS AND METHODS OF USING SAME | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2023-07-20 | — | — | WO | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-2895488-A1 | TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS | Trius Therapeutics, Inc. (US) | 2015-07-22 | — | — | EP | disclosed |
| US-9079866-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-14 | — | — | US | disclosed |
| EP-2773206-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20140221311-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140206663-A1 | TRIAZINONE COMPOUNDS | WUXI APPTECH (SHANGHAI) CO., LTD. (CN) | 2014-07-24 | — | — | US | disclosed |
| WO-2014089904-A1 | TRIAZINONE COMPOUNDS | ABBVIE INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| WO-2014085210-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-06-05 | — | — | WO | disclosed |
| WO-2014043272-A1 | TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS | TRIUS THERAPEUTICS INC. (US) | 2014-03-20 | — | — | WO | disclosed |
| WO-2013066717-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043640-B2 | Prodrugs of STAT3 inhibitors | STAT3, JAK2, STAT6 | CYP2D6 1387/4885FDPS 1812/4885DRD2 4861/4885 |
| US-20140206663-A1 | TRIAZINONE COMPOUNDS | THPO, IL5, CYP11B2 | CYP2D6 10/4885FDPS 413/4885DRD2 1999/4885 |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | CYP2D6 902/4885FDPS 251/4885DRD2 2886/4885 |
| US-20240018172-A1 | PRODRUGS OF STAT3 INHIBITORS | STAT3, JAK2, STAT1 | CYP2D6 1466/4885FDPS 1860/4885DRD2 4859/4885 |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | CYP2D6 2809/4885FDPS 2512/4885DRD2 3676/4885 |
| US-20240217989-A1 | Heteroaryl Fluoroalkenes As DGK Inhibitors | DGKA, DGKG, DGKK | CYP2D6 2446/4885FDPS 470/4885DRD2 2194/4885 |
| US-20140221311-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | CYP2D6 219/4885FDPS 196/4885DRD2 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.